Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863923 | 0.82 | PRMT6 (0.35) | ADORA1ADORA3ADORA2AADORA2BP2RY12 | |
| SCHEMBL7893477 | 0.80 | ADORA3 (0.44) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL27518665 | 0.80 | ADORA1 (0.43) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL28165438 | 0.79 | ADORA1 (0.45) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL7065334 | 0.78 | P2RY12 (0.35) | ADORA1ADORA3ADORA2AADORA2BP2RY12 | |
| SCHEMBL7251215 | 0.78 | P2RY12 (0.34) | ADORA1ADORA3ADORA2AADORA2BP2RY12 | |
| SCHEMBL7203906 | 0.77 | ADORA1 (0.42) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL9155286 | 0.76 | PRMT6 (0.39) | ADORA1ADORA3ADORA2AP2RY12 | |
| SCHEMBL7251726 | 0.76 | P2RY12 (0.33) | ADORA1ADORA3ADORA2AADORA2BP2RY12 | |
| SCHEMBL29834195 | 0.76 | ADORA1 (0.41) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1313752-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002018405-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6175005-B1 | SINGLE STAGE REACTION FOR BLOCKING HYDROXYL GROUPS ON CYCLIC ETHER BY REACTING WITH DEFINED DIFUNCTIONAL SILICON COMPOUND, WITH DEFINED MONOFUNCTIONAL SILICON GROUP, THEN WITH HYDROFLUORIC ACID IN THE PRESENCE OF A NITROGEN BASE | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | ADORA1 652/4885ADORA3 516/4885ADORA2A 287/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | ADORA1 826/4885ADORA3 636/4885ADORA2A 278/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | ADORA1 887/4885ADORA3 645/4885ADORA2A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.